Urolithin A alleviates vascular remodeling through mitochondrial SIRT3-mediated SOD2 deacetylation and antioxidation in hypertensive rats.

Key Points

• This research aims to explore how Urolithin A affects vascular remodeling in hypertensive rats through mitochondrial mechanisms.
• Administered Urolithin A to spontaneously hypertensive rats (SHR) for long-term study.
• Measured changes in VSMCs proliferation and migration.
• Assessed mitochondrial SIRT3 levels and SOD2 deacetylation and activity.
• Evaluated oxidative stress markers and vascular remodeling outcomes.
• Urolithin A treatment reduced VSMCs proliferation and migration in hypertensive rats.
• Mitochondrial SIRT3 levels increased following Urolithin A administration.
• SOD2 deacetylation was enhanced, leading to lower levels of mitochondrial reactive oxygen species (mitoROS).
• Long-term use of Urolithin A decreased hypertension and oxidative stress, improving vascular health.